Uncovering synthetic lethal interactions for therapeutic targets and predictive markers in lung adenocarcinoma

Jan Gowth Chang, Chia Cheng Chen, Yi Ying Wu, Ting Fang Che, Yi Syuan Huang, Kun Tu Yeh, Grace S. Shieh, Pan Chyr Yang

研究成果: Article同行評審

2 引文 斯高帕斯(Scopus)


Two genes are called synthetic lethal (SL) if their simultaneous mutation leads to cell death, but mutation of either individual does not. Targeting SL partners of mutated cancer genes can selectively kill cancer cells, but leave normal cells intact. We present an integrated approach to uncover SL gene pairs as novel therapeutic targets of lung adenocarcinoma (LADC). Of 24 predicted SL pairs, PARP1-TP53 was validated by RNAi knockdown to have synergistic toxicity in H1975 and invasive CL1-5 LADC cells; additionally FEN1-RAD54B, BRCA1-TP53, BRCA2-TP53 and RB1- TP53 were consistent with the literature. While metastasis remains a bottleneck in cancer treatment and inhibitors of PARP1 have been developed, this result may have therapeutic potential for LADC, in which TP53 is commonly mutated. We also demonstrated that silencing PARP1 enhanced the cell death induced by the platinumbased chemotherapy drug carboplatin in lung cancer cells (CL1-5 and H1975). IHC of RAD54B↑, BRCA1↓-RAD54B↑, FEN1(N)↑-RAD54B↑ and PARP1↑-RAD54B↑ were shown to be prognostic markers for 131 Asian LADC patients, and all markers except BRCA1↓- RAD54B↑ were further confirmed by three independent gene expression data sets (a total of 426 patients) including The Cancer Genome Atlas (TCGA) cohort of LADC. Importantly, we identified POLB-TP53 and POLB as predictive markers for the TCGA cohort (230 subjects), independent of age and stage. Thus, POLB and POLB-TP53 may be used to stratify future non-Asian LADC patients for therapeutic strategies.

頁(從 - 到)73664-73680
出版狀態Published - 2016

All Science Journal Classification (ASJC) codes

  • Oncology

指紋 深入研究「Uncovering synthetic lethal interactions for therapeutic targets and predictive markers in lung adenocarcinoma」主題。共同形成了獨特的指紋。